The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis.

Ther Adv Respir Dis · 2021 · PMC8013716 · PMID 33781141

Europe PMC DOI

hedged sentence

0.0549

closest p · 1.1× alpha

0.0549

boldest claim

The sentences

did not reach statistical significancep = 0.0549so close (0.05 < p ≤ 0.1)

The correlation between the change in UCSD-SOBQ scores and pulmonary function measurements (percent predicted FVC and DLCO) did not reach statistical significance ( p = 0.0549).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.